• Je něco špatně v tomto záznamu ?

Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum

S. Rothwell, RG. Cooper, IE. Lundberg, PK. Gregersen, MG. Hanna, PM. Machado, MK. Herbert, GJM. Pruijn, JB. Lilleker, M. Roberts, J. Bowes, MF. Seldin, J. Vencovsky, K. Danko, V. Limaye, A. Selva-O'Callaghan, H. Platt, Ø. Molberg, O. Benveniste,...

. 2017 ; 69 (5) : 1090-1099. [pub] 20170404

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031128

OBJECTIVE: Inclusion body myositis (IBM) is characterized by a combination of inflammatory and degenerative changes affecting muscle. While the primary cause of IBM is unknown, genetic factors may influence disease susceptibility. To determine genetic factors contributing to the etiology of IBM, we conducted the largest genetic association study of the disease to date, investigating immune-related genes using the Immunochip. METHODS: A total of 252 Caucasian patients with IBM were recruited from 11 countries through the Myositis Genetics Consortium and compared with 1,008 ethnically matched controls. Classic HLA alleles and amino acids were imputed using SNP2HLA. RESULTS: The HLA region was confirmed as the most strongly associated region in IBM (P = 3.58 × 10(-33) ). HLA imputation identified 3 independent associations (with HLA-DRB1*03:01, DRB1*01:01, and DRB1*13:01), although the strongest association was with amino acid positions 26 and 11 of the HLA-DRB1 molecule. No association with anti-cytosolic 5'-nucleotidase 1A-positive status was found independent of HLA-DRB1*03:01. There was no association of HLA genotypes with age at onset of IBM. Three non-HLA regions reached suggestive significance, including the chromosome 3 p21.31 region, an established risk locus for autoimmune disease, where a frameshift mutation in CCR5 is thought to be the causal variant. CONCLUSION: This is the largest, most comprehensive genetic association study to date in IBM. The data confirm that HLA is the most strongly associated region and identifies novel amino acid associations that may explain the risk in this locus. These amino acid associations differentiate IBM from polymyositis and dermatomyositis and may determine properties of the peptide-binding groove, allowing it to preferentially bind autoantigenic peptides. A novel suggestive association within the chromosome 3 p21.31 region suggests a role for CCR5.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031128
003      
CZ-PrNML
005      
20171030104955.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/art.40045 $2 doi
035    __
$a (PubMed)28086002
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rothwell, Simon $u University of Manchester, Manchester, UK.
245    10
$a Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum / $c S. Rothwell, RG. Cooper, IE. Lundberg, PK. Gregersen, MG. Hanna, PM. Machado, MK. Herbert, GJM. Pruijn, JB. Lilleker, M. Roberts, J. Bowes, MF. Seldin, J. Vencovsky, K. Danko, V. Limaye, A. Selva-O'Callaghan, H. Platt, Ø. Molberg, O. Benveniste, TRDJ. Radstake, A. Doria, J. De Bleecker, B. De Paepe, C. Gieger, T. Meitinger, J. Winkelmann, CI. Amos, WE. Ollier, L. Padyukov, AT. Lee, JA. Lamb, H. Chinoy, . ,
520    9_
$a OBJECTIVE: Inclusion body myositis (IBM) is characterized by a combination of inflammatory and degenerative changes affecting muscle. While the primary cause of IBM is unknown, genetic factors may influence disease susceptibility. To determine genetic factors contributing to the etiology of IBM, we conducted the largest genetic association study of the disease to date, investigating immune-related genes using the Immunochip. METHODS: A total of 252 Caucasian patients with IBM were recruited from 11 countries through the Myositis Genetics Consortium and compared with 1,008 ethnically matched controls. Classic HLA alleles and amino acids were imputed using SNP2HLA. RESULTS: The HLA region was confirmed as the most strongly associated region in IBM (P = 3.58 × 10(-33) ). HLA imputation identified 3 independent associations (with HLA-DRB1*03:01, DRB1*01:01, and DRB1*13:01), although the strongest association was with amino acid positions 26 and 11 of the HLA-DRB1 molecule. No association with anti-cytosolic 5'-nucleotidase 1A-positive status was found independent of HLA-DRB1*03:01. There was no association of HLA genotypes with age at onset of IBM. Three non-HLA regions reached suggestive significance, including the chromosome 3 p21.31 region, an established risk locus for autoimmune disease, where a frameshift mutation in CCR5 is thought to be the causal variant. CONCLUSION: This is the largest, most comprehensive genetic association study to date in IBM. The data confirm that HLA is the most strongly associated region and identifies novel amino acid associations that may explain the risk in this locus. These amino acid associations differentiate IBM from polymyositis and dermatomyositis and may determine properties of the peptide-binding groove, allowing it to preferentially bind autoantigenic peptides. A novel suggestive association within the chromosome 3 p21.31 region suggests a role for CCR5.
650    _2
$a věk při počátku nemoci $7 D017668
650    _2
$a autoprotilátky $x imunologie $7 D001323
650    _2
$a lidské chromozomy, pár 3 $x genetika $7 D002893
650    _2
$a běloši $x genetika $7 D044465
650    _2
$a genetické asociační studie $7 D056726
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a HLA-DRB1 řetězec $x genetika $7 D059811
650    _2
$a lidé $7 D006801
650    _2
$a myozitida s inkluzními tělísky $x genetika $x imunologie $7 D018979
650    _2
$a receptory CCR5 $x genetika $7 D019713
655    _2
$a časopisecké články $7 D016428
700    1_
$a Cooper, Robert G $u University of Liverpool, Liverpool, UK.
700    1_
$a Lundberg, Ingrid E $u Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Gregersen, Peter K $u Feinstein Institute for Medical Research, Manhasset, New York.
700    1_
$a Hanna, Michael G $u University College London, London, UK.
700    1_
$a Machado, Pedro M $u University College London, London, UK.
700    1_
$a Herbert, Megan K $u Beth Israel Deaconess Medical Center, Boston, Massachusetts, and Radboud University Nijmegen, Nijmegen, The Netherlands.
700    1_
$a Pruijn, Ger J M $u Radboud University Nijmegen, Nijmegen, The Netherlands.
700    1_
$a Lilleker, James B $u University of Manchester, Manchester, UK, and Salford Royal NHS Foundation Trust, Salford, UK.
700    1_
$a Roberts, Mark $u Salford Royal NHS Foundation Trust, Salford, UK.
700    1_
$a Bowes, John $u University of Manchester, Manchester, UK.
700    1_
$a Seldin, Michael F $u University of California, Davis.
700    1_
$a Vencovsky, Jiri $u Charles University, Prague, Czech Republic.
700    1_
$a Danko, Katalin $u University of Debrecen, Debrecen, Hungary.
700    1_
$a Limaye, Vidya $u Royal Adelaide Hospital, Adelaide, South Australia, Australia.
700    1_
$a Selva-O'Callaghan, Albert $u Vall d'Hebron General Hospital, Barcelona, Spain.
700    1_
$a Platt, Hazel $u University of Manchester, Manchester, UK.
700    1_
$a Molberg, Øyvind $u University of Oslo, Oslo, Norway.
700    1_
$a Benveniste, Olivier $u Hôpital Pitié-Salpêtrière, UPMC, Paris, France.
700    1_
$a Radstake, Timothy R D J $u University Medical Center Utrecht, Utrecht, The Netherlands.
700    1_
$a Doria, Andrea $u University of Padova, Padua, Italy.
700    1_
$a De Bleecker, Jan $u Ghent University Hospital, Ghent, Belgium.
700    1_
$a De Paepe, Boel $u Ghent University Hospital, Ghent, Belgium.
700    1_
$a Gieger, Christian $u Helmholtz Zentrum München, Neuherberg, Germany.
700    1_
$a Meitinger, Thomas $u Technische Universität München, Munich, Germany, and Helmholtz Zentrum München, Neuherberg, Germany.
700    1_
$a Winkelmann, Juliane $u Technische Universität München, Munich, Germany, and Helmholtz Zentrum München, Neuherberg, Germany.
700    1_
$a Amos, Christopher I $u Dartmouth College, Hanover, New Hampshire. $7 gn_A_00005729
700    1_
$a Ollier, William E $u University of Manchester, Manchester, UK.
700    1_
$a Padyukov, Leonid $u Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Lee, Annette T $u Feinstein Institute for Medical Research, Manhasset, New York.
700    1_
$a Lamb, Janine A $u University of Manchester, Manchester, UK.
700    1_
$a Chinoy, Hector $u Central Manchester University Hospitals NHS Foundation Trust, University of Manchester, Manchester, UK.
700    1_
$a ,
773    0_
$w MED00188151 $x 2326-5205 $g Roč. 69, č. 5 (2017), s. 1090-1099 $t Arthritis & rheumatology (Hoboken, N.J.)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28086002 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171030105044 $b ABA008
999    __
$a ok $b bmc $g 1254721 $s 992155
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 69 $c 5 $d 1090-1099 $e 20170404 $i 2326-5205 $m Arthritis & rheumatology $x MED00188151
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Možnosti archivace